MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
300.64
+3.21
+1.08%
Pre Market: 300.00 -0.64 -0.21% 05:51 10/05 EDT
OPEN
299.85
PREV CLOSE
297.43
HIGH
303.04
LOW
295.87
VOLUME
28
TURNOVER
--
52 WEEK HIGH
305.95
52 WEEK LOW
176.36
MARKET CAP
77.10B
P/E (TTM)
24.31
1D
5D
1M
3M
1Y
5Y
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash.
Benzinga · 1d ago
bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.
Zacks · 1d ago
Investing in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago would have delivered you a 87% gain
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
Simply Wall St. · 2d ago
Dow Jones Drops On Hot Inflation Data; Tesla Stock Rises Before AI Day
The Dow Jones Industrial Average dropped Friday on hot inflation data. Tesla stock fell ahead of the company's AI Day.
Investor's Business Daily · 4d ago
Vertex Pharmaceuticals' (NASDAQ:VRTX) five-year earnings growth trails the 14% YoY shareholder returns
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
Simply Wall St. · 6d ago
Vertex Nears Buy, Joins Crispr To Advance A Gene-Editing First
As biotech leaders Vertex and Crispr shoot for a gene-editing first, VRTX stock takes aim at a new breakout.
Investor's Business Daily · 6d ago
Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy
Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.
Zacks · 6d ago
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
MaxCyte Inc (NASDAQ: MXCT) has signed a 
Benzinga · 6d ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.

Webull offers kinds of Vertex Pharmaceuticals Incorporated stock information, including NASDAQ:VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.